Related Experiment Video
Updated: Sep 6, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
"Targeted Delivery-Long-Acting Adhesion-Synergistic Treatment" Integrated Adhesive Bilayer Microgels Loaded with
Yan Hu1, Shengpeng Zhu1, Fengning Lu1
1School of Pharmaceutical Science, South-Central Minzu University, Wuhan430074, PR China.
Abstract:
Oral colon-targeted drug delivery platforms are highly important for the treatment of ulcerative colitis (UC). In this study, an adhesive bilayer microgel (Cp@GTL) integrating time-lag positioning, interfacial mucoadhesive retention, and enzyme-triggered release was engineered for targeted colonic delivery. The adhesive bilayer microgels were loaded with costunolide (Cos), a natural sesquiterpene lactone exhibiting potent anti-inflammatory activity. The inner gel layer was constructed by crosslinking gelatin and low-methoxyl pectin through tannic acid and Ca2+ chelation, forming an interpenetrating network that confers colonic mucoadhesion and enzyme-responsive degradation properties. The outer shell was fabricated via polyelectrolyte complexation between anionic sodium alginate and cationic chitosan, endowing the system with resistance to gastric acid erosion through pH-responsive structural stabilization. In vitro release studies demonstrated that the microgels effectively retarded Cos release under simulated upper gastrointestinal conditions. Following oral administration in a dextran sulfate sodium (DSS)-induced UC mouse model, Cp@GTL significantly alleviated colitis symptoms, suppressed pro-inflammatory cytokine levels, and ameliorated colonic tissue damage. Furthermore, Cp@GTL exhibited prolonged colonic retention for up to 48 h with high drug accumulation at the target site, while also modulating gut microbiota composition, enhancing microbial diversity, and reducing the abundance of pathogenic bacteria, thereby synergistically contributing to the amelioration of DSS-induced colitis. This naturally derived bilayer microgel integrates time-programmed colonic positioning, interfacial mucoadhesive retention, and enzyme-triggered drug release, enabling coordinated anti-inflammatory intervention and gut microbiota regulation. It provides a promising strategy for enhancing the intestinal application of Cos in UC-associated inflammation and offers a versatile material platform and interfacial engineering approach for the targeted amelioration of intestinal inflammatory disorders.
Related Concept Videos
Drugs for Treatment of Ulcerative Colitis in IBD
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Constipation-Predominant IBS
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Oral Drug Delivery Systems: Delayed-Release Systems
